Clinical use of COX inhibitors - A consensus;Klinisk bruk av COX-hemmere - En konsensus

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 5, 2006, Pages 591-595

  Reikvam, Åsmund ^a   Hexeberg, Sofie ^b   Kvien, Tore Kristian ^c   Slørdal, Lars ^d   Aabakken, Lars ^e   Engebretsen, Lars ^f   Flatø, Berit ^e   Idsø, Njål ^b   Johnsen, Villy ^g   Kalstad, Synnøve ^b   Madsen, Steinar ^b   Mikkelsen, Knut ^h   Os, Ingrid ^f   Ræder, Johan ^f  

^a UNIVERSITY OF OSLO   (Norway)

^b Statens Legemiddelverk ^*  (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g Department of Neurology   (Norway)

^h Hospital for Rheumatic Diseases   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN SYNTHASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSENSUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PEPTIC ULCER; REVIEW; TREATMENT CONTRAINDICATION; ADULT; AGED; CHEMICALLY INDUCED DISORDER; CHILD; CHRONIC DISEASE; COMORBIDITY; DRUG CONTRAINDICATION; GASTROINTESTINAL DISEASE; MUSCULOSKELETAL DISEASE; NORWAY; PRACTICE GUIDELINE; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHILD; CHRONIC DISEASE; COMORBIDITY; CONSENSUS; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; MUSCULOSKELETAL DISEASES; NORWAY; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33645123574     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Evensen S, Spigset O, Slørdal L. COX-2-hemmere - ett skritt frem og to tilbake. Tidsskr Nor Lægeforen 2005; 125: 875-8.
2. McCarthy CJ, Crofford LJ, Greenson J et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradiction of helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1218-23.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
4. Os I. COX-2-hemmere og effekt på blodtrykk og nyrer. Tidsskr Nor Lægeforen 2003; 123: 1339-41.
5. Tacconelli S, Capone ML, Sciulli MG et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isoenzyme activity. Curr Med Res Opin 2002; 18: 503-11.
6. Chan CC, Boyce C, Brideau S et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylpenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290: 551-60.
7. Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-66.
8. Topol EJ, Falck GW. A coxib a day won't keep the doctor away. Lancet 2004; 364: 639-40.
9. Warner TD, Guilliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci 1999; 96: 7363-8.
10. Acute pain. Bandolier Extra. www.jr2.ox.ac.uk/bandolier/Extraforbando/ APain.pdf (22.12.2005).
11. Bjordal JM, Ljunggren AE, Klovning A et al. Nonsteroidal anti-inflammatory drugs, including cyclooxygenase-2 inhibitors, in osteoarthrithic knee pain: a metaanalysis of randomised placebo controlled trials. BMJ 2004; 329; 1317-23.
12. Peterson WL, Cryer B. COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 1999; 282: 1961-3.
13. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS-study: a randomised controlled trial. JAMA 2000; 284: 1247-55.
14. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case. BMJ 2002; 324: 1287-8.
15. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
16. Schnitzer TJ, Burmeister GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
17. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrage in elderly patients given selective cyclooxygenase-2-inhibitors or conventional nonsteroidal anti-inflammatory drugs. BMJ 2002; 325: 624-9.
18. Aw TJ, Haas SJ, Liew D et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Ann Intern Med 2005; 165: 490-6.
19. Bleumink GS, Feenstra J, Sturkenboom MCJM et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63: 525-34.
20. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14: 240-6.
21. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
22. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
23. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
24. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointenstinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
25. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005; 52: 1968-78.
26. Onder G, Pellicciotti F, Gambassi G et al. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004; 64: 2619-27.
27. Pomp E. Ikke-steroide antiinflammatoriske midler og kvinnelig infertilitet. Tidsskr Nor Lægeforen 2002; 122: 2295-6.
28. Skomsvoll JF, Rødevand E, Koksvik HS, et al. Reversibel infertilitet ved ikke-steroide antiinflammatoriske midler. Tidsskr Nor Lægeforen 2005; 125: 1476-8.
29. Hamad AM, Sutcliffe AM, Knox AJ. Aspirin-induced asthma. Clinical aspects, pathogenesis and management. Drugs 2004; 64: 2417-32.
30. Jones SF, Power I. Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Br J Anaesth 2005; 95: 281-4.
31. Straube S, Derry S, McQuay HJ et al. Effect of preoperative COX-II-selective NSAIDs (coxibs) on postoparative outcomes: a systematic review of randomized studies. Acta Anaesth Scand 2005; 49: 601-13.
32. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2005. E-publisert 15.9.2005.
33. Kvien TK, Brors O, Staff PH et al. Improved cost-effectiveness ratio with patient self-adjusted naproxen dosing regimen in osteoarthritis treatment. Scand J Rheumatol 1991; 20: 280-7.
34. Schumacher HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 488-92.
35. Rubin BR, Burton R, Navarra S et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004; 50: 598-606.
36. Slørdal L, Spigset O. NSAID-preparater til utvortes bruk - virker de, og bør de brukes? Tidsskr Nor Lægeforen 2002; 121: 1380-81.
37. Wong D, Wang M, Cheng Y et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204-10.
38. Titchen T, Cranswick N, Beggs S. Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol 2005; 59: 718-23.